higher dose of semaglutide FDA approves Wegovy to increase patient weight loss Novo Nordisk highlights higher-dose semaglutide

Systemic GLP-1 receptor deficiency impairs GLP-1-induced anorexia as anticipated

doi: 10.3389/fimmu.2024.1341843 Received 21 November 2023 Accepted 04 January 2024 Published 18 January 2024 Volume 15 - 2024 Edited by Ahmed Yaqinuddin, Alfaisal University, Saudi Arabia Reviewed by Suresh D

Vitamin C serves dual role of a prooxidant and an antioxidant [23]

The study investigated the effects of once-weekly injections of semaglutide on albuminuria and kidney health in patients with CKD and obesity but without diabetes

6) Sleep Apnea: A Novel Approach to Improved Sleep Quality GLP-1 medications, particularly tirzepatide, are garnering attention for their potential in treating sleep apnea, a common sleep disorder characterized by pauses in breathing during sleep